Archives of Virology

, Volume 152, Issue 8, pp 1447–1455 | Cite as

Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo

  • L. Shi
  • H. Xiong
  • J. He
  • H. Deng
  • Q. Li
  • Q. Zhong
  • W. Hou
  • L. Cheng
  • H. Xiao
  • Z. Yang
Article

Summary

Arbidol, ethyl-6-bromo-4-[(dimethylamino)-methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-in dole-3-carboxylate hydrochloride monohydrate, is an antiviral chemical agent. In this report, we studied the antiviral activity of arbidol against a panel of human respiratory viruses, namely influenza A virus (FLU-A, A/PR/8/34 H1N1), respiratory syncytial virus (RSV), human rhinovirus type 14 (HRV 14), coxsackie virus B3 (CVB3) and adenovirus type 7 (AdV-7) in vitro in cell culture. Arbidol was found to present potent inhibitory activity against enveloped and non-enveloped RNA viruses, including FLU-A, RSV, HRV 14 and CVB3 when added before, during, or after viral infection, with 50% inhibitory concentration (IC50) ranging from 2.7 to 13.8 µg/ml. However, arbidol showed selective antiviral activity against AdV-7, a DNA virus, only when added after infection (therapeutic index (TI) = 5.5). Orally administered arbidol at 50 or 100 mg/kg/day beginning 24 h pre-virus exposure for 6 days significantly reduced mean pulmonary virus yields and the rate of mortality in mice infected with FLU-A (A/PR/8/34 H1N1). Our results suggest that arbidol has the ability to elicit protective broad-spectrum antiviral activity against a number of human pathogenic respiratory viruses.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anonymous,  1999ArbidolDrugs R&D2171172Google Scholar
  2. Boriskin, YS, Pecheur, EI, Polyak, SJ 2006Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infectionVirol J356PubMedCrossRefGoogle Scholar
  3. Brooks, MJ, Sasadeusz, JJ, Tannock, GA 2004Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what’s in the pipeline?Pulmonary Med10197203CrossRefGoogle Scholar
  4. Burger, RA, Billingsley, JL, Huffman, JH, Bailey, KW, Kim, CU 2000Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected miceImmunopharmacology474552PubMedCrossRefGoogle Scholar
  5. Chai, H, Zhao, Y, Zhao, C, Gong, P 2006Synthesis and in vitro anti-hepatitis B virus activities of some ethyl-6-bromo-5-hydroxy-1H-indole-3-carboxylatesBioorg Med Chem14911917PubMedCrossRefGoogle Scholar
  6. Fedyakina, IT, Lenyova, IA, Yamnikova, SS, Glushkov, RG 2005Sensitivity of influenza A/H5 viruses isolated from wild birds on the territory of Russia to arbidol in the cultured MDCK cellsVopr Virusol503235Google Scholar
  7. Fleming, DM, Cross, KW 1993Respiratory syncytial virus or influenzaLancet32415071510CrossRefGoogle Scholar
  8. Garozzo, A, Cutri, CC, Castro, A, Tempera, G, Guerrera, F, Sarva, MC, Geremia, E 2000Anti-rhinovirus activity of 3-methylthio-5-aryl-4-isothiazolecarbonitrile derivativesAntiviral Res45199210PubMedCrossRefGoogle Scholar
  9. Gern, JE, Busse, WW 1999Association of rhinovirus infections with asthmaClin Microbiol Rev12918PubMedGoogle Scholar
  10. Guskova, TA, Leneva, IA, Fedyakina, IT, Chistyakov, VV, Glushkov, RG 1999Arbidol kinetics and its effect on influenza A virus replication in MDCK cell cultureChemico Pharmaceut J61417Google Scholar
  11. Hayden, FG, Atmar, RL, Schilling, M, Johnson, C, Poretz, D, Paar, D, Huson, L, Ward, P, Mills, RG 1999Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenzaN Engl J Med34113361343PubMedCrossRefGoogle Scholar
  12. Hayden, FG, Belshe, RB, Villaneueva, C, Lanno, R, Hughes, C, Small, I, Dutkowski, R, Ward, P, Carr, J 2004Management of influenza in households: a prospective randomized comparison of oseltamivir treatment with or without post-exposure prophylaxisJ Infect Dis189440449PubMedCrossRefGoogle Scholar
  13. Kaiser, L, Wat, C, Mills, T, Mahoney, P, Ward, P, Hayden, F 2003Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizationsArch Intern Med16316671672PubMedCrossRefGoogle Scholar
  14. Kiso, M, Mitamura, K, Sakai-Tagawa, Y, Shiraishi, K, Kawakami, C, Kimura, K, Hayden, F, Sugaya, N, Kawaoka, Y 2004Resistant influenza A viruses in children treated with oseltamivir: descriptive studyLancet364759765PubMedCrossRefGoogle Scholar
  15. Kneyber, MCJ, Moll, HA, Groot, RD 2000Treatment and prevention of respiratory syncytial virus infectionEur J Pediatr159399411PubMedCrossRefGoogle Scholar
  16. Leneva IA, Fedyakina IT, Fadeeva NI, Guskova TA (1996) Effect of a new antiviral drug arbidol on influenza virus replication. Xth International Congress of Virology Aug: 11–16Google Scholar
  17. Leneva, IA, Hay, A 1998The mechanism of action of arbidol against influenza virus: selection and characterization of arbidol-resistant mutantsAntiviral Res3789Google Scholar
  18. Li, Yaolan, Paul, PH 2005Antiviral activity and mode of action of caffeoylquinic acids from Schefflera heptaphylla (L.) FordinAntiviral Res6819PubMedCrossRefGoogle Scholar
  19. Maitreyi, RS, Broor, S, Kabra, SK 2000Rapid detection of respiratory viruses by centrifugation enhanced cultures from children with acute lower respiratory tract infectionsJ Clin Virol164147PubMedCrossRefGoogle Scholar
  20. Markland, W, Mcquaid, TJ, Jain, J, Kwong, AD 2000Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferonAntimicro Agents Chemother44859866CrossRefGoogle Scholar
  21. Marshall, NJ, Goodwin, CJ, Holt, SJ 1995A critical assessement of the use of microculture tetrazolium assays to measure cell growth and functionGrowth Regulation56984PubMedGoogle Scholar
  22. Monobe, H, Ishibashi, T, Nomura, Y, Shinogami, M, Yano, J 2003Role of respiratory viruses in children with acute otitis mediaInt J Pediatr Otorhinolaryngol67801806PubMedCrossRefGoogle Scholar
  23. Mosmann, T 1983Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assaysJ Immunol Methods655563PubMedCrossRefGoogle Scholar
  24. Munoz, FM, Galasso, GJ, Gwaltney, JM, Hayden, FG, Murphy, B, Webster, R, Wright, P, Couch, RB 2000Current research on influenza and other respiratory viruses: II. International SymposiumAntiviral Res4691124PubMedCrossRefGoogle Scholar
  25. Papadopoulos, NG, Bates, PJ, Bardin, PG, Papi, A, Leir, SH, Fraenkel, DJ 2000Rhinoviruses infect the lower airwaysJ Infect Dis18118751884PubMedCrossRefGoogle Scholar
  26. Patel, DD, Kapoor, A, Ayyagari, A, Dhole, TN 2004Development of a simple restriction fragment length polymorphism assay for subtyping of coxsackie B virusesJ Virol Methods120167172PubMedCrossRefGoogle Scholar
  27. Reed, LJ, Muench, HA 1938A simple method of estimating fifty percent endpointsAm J Hyg27493497Google Scholar
  28. Schulman, J 1968Effect of L-amantanamine hydrochloride(amantadine HCL) and methyl-L-adamantanethylamine hydrochloride (rimantadine HCL) on teansmission of influenza virus infection in miceProc Soc Exp Biol Med12811731178Google Scholar
  29. Sudo, K, Miyazaki, Y, Kojima, N, Kobayashi, M, Suzuki, H, Shintani, M, Shimizu, Y 2005YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of actionAntiviral Res65125131PubMedCrossRefGoogle Scholar
  30. Thompson, WW, Shay, DK, Weintraub, E, Brammer, L, Cox, N, Anderson, LJ, Fukuda, K 2003Mortality associated with influenza and respiratory syncytial virus in the United StatesJAMA289179186PubMedCrossRefGoogle Scholar
  31. World Health Organization (WHO) (2004) World Health Organization: Influenza. http://www.who.int/mediacentre/factsheets/2003/fs211/en/
  32. Wyde, PR 1998Respiratory syncytial virus (RSV) disease and prospects for its controlAntiviral Res396379PubMedCrossRefGoogle Scholar
  33. Xiang, X, Qiu, D, Chan, KP, Chan, SH, Hegele, RG, Tan, WC 2002Comparison of three methods for respiratory virus detection between induced sputum and nasopharyngeal aspirate specimens in acute asthmaJ Virol Methods101127133PubMedCrossRefGoogle Scholar
  34. Zarubaev, VV, Slita, AV, Krivitskaya, VZ, Sirotkin, AK, Kovalenko, AL, Chatterjee, NK 2003Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro Antiviral Res58131137PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • L. Shi
    • 1
  • H. Xiong
    • 1
  • J. He
    • 1
  • H. Deng
    • 1
  • Q. Li
    • 1
  • Q. Zhong
    • 1
  • W. Hou
    • 1
  • L. Cheng
    • 1
  • H. Xiao
    • 1
  • Z. Yang
    • 1
  1. 1.State Key Laboratory of Virology, Institute of Medical VirologyWuhan UniversityWuhanP.R. China

Personalised recommendations